Literature DB >> 3026954

Organ-specific autoimmunity: a 1986 overview.

G F Bottazzo, I Todd, R Mirakian, A Belfiore, R Pujol-Borrell.   

Abstract

The normally functioning immune system is subject to intricate networks of regulatory mechanisms: it is therefore not surprising to find that autoimmune diseases present a complex pathogenic picture in which the relative contributions of various factors probably determine the precise nature and course of disease. This is particularly evident in the effector mechanisms of organ-specific autoimmunity which are described in this chapter. These ultimately give rise to the disease symptoms, and can be directly cytotoxic, or may either stimulate or block functional activity or growth of the target cells. Their various contributions to human diseases are becoming more firmly established, as in Type I diabetes, or are only now being described, as in the case of EC-Ab in protracted diarrhea of infancy and as evidenced by the growing lists of receptor-stimulating or -blocking antibodies. The nature and precise location of relevant autoantigens is also coming under closer scrutiny. The answers to the question of why these diseases arise in the first place remain more elusive. However, it is again likely that a variety of factors can contribute. The attractive possibility of a role for idiotypic interactions is gaining ground, particularly within the context of antibodies to hormones and their receptors. Another potential mechanism which we believe may be of central importance, particularly in the development of organ-specific destructive autoimmunity, and which we have discussed here in detail, is the aberrant expression of HLA Class II molecules by target cells. Whether this is actually an initiating factor is presently not known, but its potential for promoting pathogenesis both early and late in the process is clear. Furthermore, the complex nature of the regulation of epithelial Class II expression may help to explain the heterogeneity of features and course of disease in different patients with the same underlying pathology. All these advances in our basic understanding of the disease processes should ultimately lead to more effective and specific means of therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026954      PMCID: PMC7165626          DOI: 10.1111/j.1600-065x.1986.tb01168.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  120 in total

1.  Anti-thyroid peroxidase antibody in patients with autoimmune thyroid disease: possible identity with anti-microsomal antibody.

Authors:  L Portmann; N Hamada; G Heinrich; L J DeGroot
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

2.  Parathyroid cell surface autoantibodies that inhibit parathyroid hormone secretion from dispersed human parathyroid cells.

Authors:  J T Posillico; J Wortsman; S Srikanta; G S Eisenbarth; L E Mallette; E M Brown
Journal:  J Bone Miner Res       Date:  1986-10       Impact factor: 6.741

3.  Beta-cell damage in diabetic insulitis: are we approaching a solution?

Authors:  G F Bottazzo
Journal:  Diabetologia       Date:  1984-04       Impact factor: 10.122

4.  Viral particles induce Ia antigen expression on astrocytes.

Authors:  P T Massa; R Dörries; V ter Meulen
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

5.  Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins.

Authors:  S Baekkeskov; J H Nielsen; B Marner; T Bilde; J Ludvigsson; A Lernmark
Journal:  Nature       Date:  1982-07-08       Impact factor: 49.962

6.  Thyrotrophin stimulation of mitogenesis of the rat thyroid cell strain FRTL-5: a metaphase index assay for the detection of thyroid growth stimulators.

Authors:  P A Ealey; J M Emmerson; S P Bidey; N J Marshall
Journal:  J Endocrinol       Date:  1985-08       Impact factor: 4.286

7.  Presence of the organ-specific 'microsomal' autoantigen on the surface of human thyroid cells in culture: its involvement in complement-mediated cytotoxicity.

Authors:  E L Khoury; L Hammond; G F Bottazzo; D Doniach
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

8.  Autoantibodies to vasopressin cells in idiopathic diabetes insipidus: evidence for an autoimmune variant.

Authors:  W A Scherbaum; G F Bottazzo
Journal:  Lancet       Date:  1983-04-23       Impact factor: 79.321

9.  Thyroid growth-blocking antibodies in primary myxoedema.

Authors:  H A Drexhage; G F Bottazzo; L Bitensky; J Chayen; D Doniach
Journal:  Nature       Date:  1981-02-12       Impact factor: 49.962

10.  Surface-reactive antibodies to human adrenal cells in Addison's disease.

Authors:  E L Khoury; L Hammond; G F Bottazzo; D Doniach
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

View more
  50 in total

1.  Induction of HLA-DR expression on human myoblasts with interferon-gamma.

Authors:  R Hohlfeld; A G Engel
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 2.  Transcriptional regulation of HLA class-II genes.

Authors:  B M Peterlin; G Andersson; E Lötscher; S Tsang
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Enhancement of thyrocyte HLA class II expression by thyroid stimulating hormone.

Authors:  I Todd; R Pujol-Borrell; L J Hammond; J M McNally; M Feldmann; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

4.  B-cell factor 1 is required for optimal expression of the DRA promoter in B cells.

Authors:  C F Voliva; A Aronheim; M D Walker; B M Peterlin
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

5.  Recognition of major histocompatibility complex antigens on cultured human biliary epithelial cells by alloreactive lymphocytes.

Authors:  S L Saidman; R J Duquesnoy; A Zeevi; J J Fung; T E Starzl; A J Demetris
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

Review 6.  I-E transgenic mice: a model system to dissect the regulation and function of MHC class II genes in vivo.

Authors:  L C Burkly; D Lo; R L Brinster; R A Flavell
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

7.  Two DNA-binding proteins discriminate between the promoters of different members of the major histocompatibility complex class II multigene family.

Authors:  M Kobr; W Reith; C Herrero-Sanchez; B Mach
Journal:  Mol Cell Biol       Date:  1990-03       Impact factor: 4.272

Review 8.  Potential roles of neutrophils in maintaining the health and productivity of dairy cows during various physiological and physiopathological conditions: a review.

Authors:  Mohanned Naif Alhussien; Ajay Kumar Dang
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

9.  The MHC class II E beta promoter: a complex arrangement of positive and negative elements determines B cell and interferon-gamma (IFN-gamma) regulated expression.

Authors:  D Thanos; M Gregoriou; D Stravopodis; K Liapaki; T Makatounakis; J Papamatheakis
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

10.  Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjögren's syndrome compared with obstructive sialadenitis.

Authors:  P S Thrane; T S Halstensen; H R Haanaes; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.